AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23143411 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine extended release (XR), 150-300 mg/day
Number of subjects: 23
Study 23143773 — intervention group
Group type: EXPERIMENTAL
Intervention: FP85A alone
Number of subjects: 3
Study 23143773 — intervention group
Group type: EXPERIMENTAL
Intervention: FP85A followed by MVA85A
Number of subjects: 3
Study 23143773 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 3
Study 23143773 — intervention group
Group type: EXPERIMENTAL
Intervention: FP85A and MVA85A
Number of subjects: 3
Study 23143939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac tromethamine 31.5 mg (15.75 mg per nostril)
Number of subjects: 30
Study 23144193 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg by mouth once daily on days 1-28 of a 28-day cycle with rituximab administered weekly during cycle one and then on day one of subsequent cycles
Number of subjects: 26
Study 23144193 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus in combination with rituximab
Number of subjects: 26
Study 23144200 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan, lenalidomide, and dexamethasone; melphalan 5 mg/m²/day for 4 days, lenalidomide 10 mg/day for 21 days, dexamethasone 20-40 mg once a week every 28 days for 12 cycles.
Number of subjects: 16
Study 23144326 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide significant single nucleotide polymorphisms (SNPs) affecting Clara cell secretory protein (CC16) levels
Number of subjects: 1951
Study 23144326 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide significant single nucleotide polymorphisms (SNPs) affecting surfactant protein D (SP-D) levels
Number of subjects: 1951
Study 23144326 — intervention group
Group type: COMPARATOR
Intervention: Candidate SNPs associated with COPD susceptibility
Number of subjects: 1951
Study 23145537 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate, 220 mg per capsule, two capsules per day for three months
Number of subjects: 37
Study 23145537 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation
Number of subjects: 37
Study 23145922 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention by pharmacists and other healthcare professionals
Number of subjects: 477
Study 23146246 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR149415 100 mg
Number of subjects: 0
Study 23146246 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR149415 250 mg
Number of subjects: 0
Study 23146246 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 0
Study 23146246 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 0
Study 23146246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23146560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis withdrawal symptoms reported by participants (113 out of 120, 94.2%)
Number of subjects: 120
Study 23146560 — intervention group
Group type: EXPERIMENTAL
Intervention: Actions taken to relieve withdrawal symptoms (104 out of 120, 92.0%)
Number of subjects: 120
Study 23146956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1250mg/day and Sorafenib 400mg twice daily (RPTD)
Number of subjects: 30
Study 23146956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and Sorafenib combination treatment
Number of subjects: 30
Study 23147218 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-751 125 mg orally twice daily for 7 days with carboplatin AUC 6
Number of subjects: 20
Study 23147218 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-751 with carboplatin
Number of subjects: 20
Study 23148122 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23148516 — intervention group
Group type: EXPERIMENTAL
Intervention: Class-based HPV vaccination
Number of subjects: 134
Study 23148516 — intervention group
Group type: COMPARATOR
Intervention: Age-based HPV vaccination
Number of subjects: 134
Study 23148516 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaled-up class-based vaccination
Number of subjects: 134
Study 23148516 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine delivery excluding vaccine costs
Number of subjects: 134
Study 23148516 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial scaled-up costs excluding vaccine and salaries
Number of subjects: 134
Study 23148799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan auto-injector (6 mg subcutaneous)
Number of subjects: 63
Study 23149277 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQCT-based analysis of spinal bone density and microstructure, finite element analysis (FEA)
Number of subjects: 73
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (55.5%)
Number of subjects: 4467
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity (48.2%)
Number of subjects: 4467
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension (46.6%)
Number of subjects: 4467
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia (34.9%)
Number of subjects: 4467
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (22.3%)
Number of subjects: 4467
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk alcohol consumption (33.0%)
Number of subjects: 4467
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (20.6%)
Number of subjects: 4467
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine (26.5%)
Number of subjects: 4467
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity (74% in women aged 25 years or older)
Number of subjects: 4467
Study 23150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 4467
Study 23150682 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated triglycerides (TGs)
Number of subjects: 219
Study 23150682 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased free fatty acids (FFAs)
Number of subjects: 219
Study 23150931 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence using written logs
Number of subjects: 135
Study 23150931 — intervention group
Group type: COMPARATOR
Intervention: Electronic recording of device usage
Number of subjects: 135
Study 23151076 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells (UCMSCs) therapy
Number of subjects: 16
Study 23151237 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Administered Comorbidity Questionnaire (SCQ)
Number of subjects: 525
Study 23151237 — intervention group
Group type: COMPARATOR
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 525
Study 23151373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with deferasirox (DFX, 20-30 mg/kg daily) and deferoxamine (DFO, 35-50 mg/kg on 3-7 days/week)
Number of subjects: 22
Study 23151395 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week non-surgical treatment programme (patient education, exercise, diet, insoles, paracetamol and/or NSAIDs)
Number of subjects: 100
Study 23151395 — intervention group
Group type: COMPARATOR
Intervention: Usual care (two information leaflets on KOA and advice regarding non-surgical treatment)
Number of subjects: 100
Study 23151395 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week non-surgical treatment programme
Number of subjects: 100
Study 23151395 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 23151831 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-assisted reading
Number of subjects: 618
Study 23151831 — intervention group
Group type: COMPARATOR
Intervention: Unassisted reading
Number of subjects: 618
Study 23152364 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer drug eluting stents (BP-DES)
Number of subjects: 5834
Study 23152364 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer drug eluting stents (DP-DES)
Number of subjects: 5834
Study 23153506 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-loaded anti-EGFR immunoliposomes (anti-EGFR ILs-dox) at doses of 5 mg/m(2), 10 mg/m(2), 20 mg/m(2), 30 mg/m(2), 40 mg/m(2), 50 mg/m(2), and 60 mg/m(2) intravenously infused once every 4 weeks for a maximum of six cycles
Number of subjects: 29
Study 23154208 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine AQP1 levels in patients with kidney cancer
Number of subjects: 165
Study 23154208 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine PLIN2 levels in patients with kidney cancer
Number of subjects: 165
Study 23154208 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine AQP1 levels after tumor excision
Number of subjects: 165
Study 23154208 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine PLIN2 levels after tumor excision
Number of subjects: 165
Study 23154208 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between urine AQP1 and PLIN2 levels and tumor size
Number of subjects: 165
Study 23154208 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine AQP1 levels in patients with kidney cancer compared to common kidney diseases
Number of subjects: 165
Study 23154208 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine PLIN2 levels in patients with kidney cancer compared to common kidney diseases
Number of subjects: 165
Study 23154208 — intervention group
Group type: COMPARATOR
Intervention: Specificity of urine AQP1 and PLIN2 to identify kidney cancer
Number of subjects: 165
Study 23154459 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 29
Study 23154459 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe NPDR cases
Number of subjects: 29
Study 23154470 — intervention group
Group type: EXPERIMENTAL
Intervention: F-FDG PET/CT
Number of subjects: 12
Study 23155695 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripubertal girls
Number of subjects: 46
Study 23155695 — intervention group
Group type: COMPARATOR
Intervention: Control group (overweight African-American women)
Number of subjects: 46
Study 23157720 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGylated interferon (PEG-IFN) α-2a or PEG-INF α-2b combined with daily ribavirin (1000-1200 mg/day) for 48 weeks
Number of subjects: 388
Study 23157877 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained algorithm for PET/CT image registration
Number of subjects: 10
Study 23157877 — intervention group
Group type: COMPARATOR
Intervention: Unconstrained algorithm for PET/CT image registration
Number of subjects: 10
Study 23157946 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC gene signature expression in primary PDAC
Number of subjects: 6
Study 23158458 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional variants of HTR2A, including polymorphisms rs6311, rs76665058, and an unannotated SNP affecting mRNA expression and splicing.
Number of subjects: 10
Study 23158458 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted analysis of HTR2A in the STAR*D study.
Number of subjects: 10
Study 23159367 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings of patients with CRC
Number of subjects: 374
Study 23159367 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 374
Study 23160344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure biofeedback test (maintaining pressure of 40 ± 5 mmHg)
Number of subjects: 49
Study 23160344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure biofeedback test
Number of subjects: 49
Study 23160468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose donor lymphocyte infusions beginning 5 months after transplantation
Number of subjects: 24
Study 23160468 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1-CTL responses before allogeneic transplantation
Number of subjects: 24
Study 23160468 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 expression in bone marrow
Number of subjects: 24
Study 23161291 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy with therapeutic procedures
Number of subjects: 423
Study 23161291 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors post-endoscopy
Number of subjects: 423
Study 23161291 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >65 years, hematemesis or shock/syncope, duodenal ulcer diagnosis
Number of subjects: 423
Study 23161291 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients older than 65 years, comorbidities, shock/syncope presentation, time to endoscopy
Number of subjects: 423
Study 23161291 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, non-steroidal anti-inflammatory drugs, or warfarin at baseline
Number of subjects: 423
Study 23161291 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions other than intravenous fluid or red blood cells within 12 hours of presentation
Number of subjects: 423
Study 23164174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated radiosurgery (10 fractions or 5 fractions depending on life expectancy)
Number of subjects: 60
Study 23164174 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (1-10 fractions, total doses of 8-30 Gy)
Number of subjects: 60
Study 23164314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-based lipid emulsion (FOLE) monotherapy
Number of subjects: 57
Study 23164485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 1124
Study 23164592 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with IPAH receiving combinations of PAH drugs
Number of subjects: 587
Study 23164592 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with IPAH
Number of subjects: 587
Study 23164592 — intervention group
Group type: COMPARATOR
Intervention: Younger patients with IPAH
Number of subjects: 587
Study 23164593 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 124
Study 23164593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 124
Study 23164593 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 124
Study 23164593 — intervention group
Group type: EXPERIMENTAL
Intervention: Stents with nominal diameters ≥ 2.75 mm
Number of subjects: 124
Study 23164721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (core temperature <35°C before reperfusion)
Number of subjects: 197
Study 23164721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypothermia)
Number of subjects: 197
Study 23164766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary embolism diagnosed by computed tomography
Number of subjects: 176
Study 23164766 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation after pulmonary embolism diagnosis
Number of subjects: 176
Study 23164766 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep venous thrombosis detected by compression ultrasonography
Number of subjects: 176
Study 23164766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-limb deep venous thrombosis
Number of subjects: 176
Study 23164766 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-limb deep venous thrombosis
Number of subjects: 176
Study 23164766 — intervention group
Group type: COMPARATOR
Intervention: Comparison of patients with and without pulmonary embolism
Number of subjects: 176
Study 23166141 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study 23166141 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 0
Study 23168248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic [18F]FDG PET scan
Number of subjects: 13
Study 23168248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic [15O]H2O scan
Number of subjects: 13
Study 23168248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear regression analysis
Number of subjects: 13
Study 23168248 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-derived input function (IDIF)
Number of subjects: 13
Study 23168248 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sampler derived input function (BSIF)
Number of subjects: 13
Study 23168578 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 80
Study 23168578 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented infants
Number of subjects: 80
Study 23168578 — intervention group
Group type: EXPERIMENTAL
Intervention: CHr cutoff level of 26.9 pg at 4 months
Number of subjects: 80
Study 23168606 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted pelvic muscle training (BFB)
Number of subjects: 183
Study 23169500 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib therapy
Number of subjects: 1
Study 23169503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin 40 mg/m(2), rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2), vincristine 1.4 mg/m(2), prednisone 100 mg orally on days 1 through 5, with concomitant antiretroviral therapy
Number of subjects: 40
Study 23169518 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vincristine sulfate liposome injection (VSLI) 2.25 mg/m(2), administered once per week until response, progression, toxicity, or pursuit of HCT.
Number of subjects: 65
Study 23169778 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 299
Study 23170854 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol loading dose (20 mg · kg(-1))
Number of subjects: 60
Study 23170854 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol monotherapy
Number of subjects: 60
Study 23171483 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Impairment Screen (MIS) with alternate versions
Number of subjects: 1803
Study 23171483 — intervention group
Group type: COMPARATOR
Intervention: Memory Impairment Screen (MIS) with the same version at first follow-up
Number of subjects: 1803
Study 23171483 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean scores from repeated testing
Number of subjects: 1803
Study 23171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (1-hour infusion)
Number of subjects: 44
Study 23171747 — intervention group
Group type: EXPERIMENTAL
Intervention: NOTSSdk (customized Non-Technical Skills for Surgeons rating system)
Number of subjects: 72
Study 23171747 — intervention group
Group type: EXPERIMENTAL
Intervention: NOTSSdk
Number of subjects: 72
Study 23171803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-based hydration (154 mEq/L at 3 ml Kg-1 for one hour followed by 1 ml Kg-1 for six hours) with high-dose N-acetylcysteine (NAC)
Number of subjects: 524
Study 23171803 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline hydration (1 ml Kg-1 for 24 hours) with high-dose N-acetylcysteine (NAC)
Number of subjects: 524
Study 23171803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-based hydration with high-dose NAC
Number of subjects: 524
Study 23171803 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline hydration with high-dose NAC
Number of subjects: 524
Study 23172848 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V Everolimus-eluting stent
Number of subjects: 673
Study 23172858 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference measurement at minimal waist
Number of subjects: 371
Study 23172858 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference measurement at midpoint between the iliac crest and the lowest rib
Number of subjects: 371
Study 23172858 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference measurement at superior border of the iliac crest
Number of subjects: 371
Study 23172858 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference measurement at umbilicus
Number of subjects: 371
Study 23172858 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between WC and logVAT
Number of subjects: 371
Study 23172858 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between WC and cardiometabolic risk factors
Number of subjects: 371
Study 23173902 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for Measuring Motivational Interviewing Skills (EVEM questionnaire)
Number of subjects: 362
Study 23173902 — intervention group
Group type: EXPERIMENTAL
Intervention: Video recorded interviews
Number of subjects: 362
Study 23174632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 6139
Study 23174632 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 6139
Study 23174636 — intervention group
Group type: EXPERIMENTAL
Intervention: LAD occlusion
Number of subjects: 65
Study 23174636 — intervention group
Group type: COMPARATOR
Intervention: Diagonal branch occlusion
Number of subjects: 65
Study 23175735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based case management (CM)
Number of subjects: 280
Study 23175735 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 280
Study 23175738 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (five psychoeducational consultations and a 12-week exercise training programme)
Number of subjects: 150
Study 23175738 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 23176444 — intervention group
Group type: EXPERIMENTAL
Intervention: PUSH + PULL
Number of subjects: 670
Study 23176444 — intervention group
Group type: COMPARATOR
Intervention: PULL
Number of subjects: 670
Study 23176611 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat hydrochloride, 150 mg orally every-other-day
Number of subjects: 9
Study 23176709 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial dry needling (SDN)
Number of subjects: 77
Study 23176709 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 77
Study 23176709 — intervention group
Group type: COMPARATOR
Intervention: All participants (SDN and DDN)
Number of subjects: 77
Study 23176709 — intervention group
Group type: COMPARATOR
Intervention: Superficial dry needling (SDN) and Deep dry needling (DDN)
Number of subjects: 77
Study 23178234 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parenting interventions for disruptive behaviors
Number of subjects: 0
Study 23178234 — intervention group
Group type: COMPARATOR
Intervention: Behavioral parenting interventions for anxiety
Number of subjects: 0